Member Info for Babbler2

https://www.telegraph.co.uk/business/2019/01/10/biotech-minnow-angle-triumphs-cancer-blood-testing-kit/

Morning. yup. you were in before the news weren't you,? Of course I sold ages ago...

might have sold into today's spike if I was though...mice...

https://www.telegraph.co.uk/business/2019/01/10/biotech-minnow-angle-triumphs-cancer-blood-testing-kit/

I'm pretty sure it isn't part of aim and is main market listed... but worrying.... if true?

certainly is... but been waiting ages for the damn buy back that was promised... lol.

Well today shall be known as pharma day lmao. Agl amazing news for patients imo.

Actually closed at 74 mid.

who knows... depends on twitter and other coverage.

looks like a lot sold here for agl.... Will be watching both closely tomorrow

closed at 72 mid. well done. more tomorrow? might buy on open.

if that was a 7am rns it would be at 90 by close. Well done

Nice. must be national pharma day... lol.

Here comes the pre close sell off :p... Guess will leave them in. Its only profit shares now anyway

Likely wakeup on next news. Alert set.

certainly big trades both ways ... delayed of course.

you might be right who knows...

Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, is pleased to announce that the Scottish Medicines Consortium (SMC) has today approved the routine use of Alkindi(R) (hydrocortisone granules in capsules for opening) as the first-line treatment of young children with adrenal insufficiency aged from birth to less than six years of age for whom hydrocortisone must be individually prepared by manipulation such as by compounding (or crushing) or by production of special solutions in order to produce age-appropriate doses, or hydrocortisone given as off-label buccal tablets

a lot happening this year

We continue to be pleased with the progress of the commercial roll-out of our lead product, Alkindi(R) , across Europe following its launch in May 2018. We expect by early 2019 that Alkindi(R) will be commercially available in the UK, Germany, Austria and the Nordic region. We also remain focused on completing pricing negotiations in key European territories as well as the finalisation of the clinical data package for Alkindi(R) in the US for submission to the FDA."

forget today...

. There continues to be a significant unmet need to improve patient outcomes in this debilitating disease and we therefore look forward to discussing our data package with European regulators to agree a pathway forward."

Looking like a 50p close coming. imo.

Talk about volotile.

Another 5k buy...